TP53 and cancer: Obtained results altogether suggested that the combined blockade of exportin 1 and RUVBL1/2 complex, as well as inhibiting exportin 1 and HSPA9, are promising targeted therapeutic approaches at least against cancers driven by mutant TP53, mutant KRAS, and/or hyperactive MYC.